Cover Image
市場調查報告書

蛋白激酶C-ε (nPKC-ε/EC 2.7.11.13):開發中產品分析

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363123
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
蛋白激酶C-ε (nPKC-ε/EC 2.7.11.13):開發中產品分析 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 42 Pages
簡介

本報告提供全球各國的蛋白激酶C-ε (nPKC-ε/EC 2.7.11.13) 治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品的一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 蛋白激酶C-ε (nPKC-ε/EC 2.7.11.13)的概要
  • 治療藥的開發
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Hadasit Medical Research Services & Development Ltd
    • VM Discovery, Inc.
  • 藥物簡介
    • Bryostatin-1
    • DHACP-6
    • 缺血性發作的εPKC活性化用小分子
    • 外傷性腦功能障礙的εPKC活性化用小分子
    • 神經症的εPKC活性化用小分子
    • 第二型糖尿病、胰島素抗性的蛋白激酶C抑制用合成肽
    • VMD-1201
    • VMD-2202
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1050TDB

Summary:

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017, outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Oncology which include indications Alzheimer's Disease, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alcohol Addiction, Fragile X Syndrome, Head And Neck Cancer, Ischemic Stroke, Neurology, Rett Syndrome and Traumatic Brain Injury.

Furthermore, this report also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
  • The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
    • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
    • Bryostatin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profilea
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VMD-1201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VMD-2202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 19, 2017: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017
      • Jun 29, 2017: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting
      • May 01, 2017: NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease
      • Apr 28, 2017: Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017
      • Feb 28, 2017: Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia
      • Nov 22, 2016: Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimers Disease
      • Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead
      • Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
      • Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease
      • Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
      • Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer's Disease
      • Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer's Disease
      • Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer's Disease
      • Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference
      • Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top